Thus, the indistinguishable prevalence of BRAF-specific antibodies among RA, pSS, and SLE patients raises the possibility that the cytokine environment in these diseases is beneficial for anti-BRAF or anti-P25 production. Here, BRAF is linked to rheumatoid arthritis.